| JAMRX | VIGAX | JAMRX / VIGAX | |
| Total Expense Ratio | 0.79 | 0.05 | 1,580% |
| Annual Report Gross Expense Ratio | 0.79 | 0.05 | 1,580% |
| Fund Existence | 33 years | 25 years | - |
| Gain YTD | 15.428 | 16.783 | 92% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 3000 | 83% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 29.4B | 357B | 8% |
| Annual Yield % from dividends | 0.00 | 0.40 | - |
| Returns for 1 year | 12.87 | 19.95 | 65% |
| Returns for 3 years | 99.24 | 111.81 | 89% |
| Returns for 5 years | 55.45 | 100.53 | 55% |
| Returns for 10 years | 112.92 | 337.63 | 33% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BBC | 33.75 | 0.87 | +2.65% |
| Virtus LifeSci Biotech Clinical Trls ETF | |||
| HQL | 17.25 | 0.09 | +0.52% |
| abrdn Life Sciences Investors | |||
| JMUB | 50.72 | 0.08 | +0.15% |
| JPMorgan Municipal ETF | |||
| NSEP | 28.55 | -0.10 | -0.35% |
| Innovator Growth-100 Pwr Buffr ETF - Sep | |||
| PFO | 9.51 | -0.05 | -0.52% |
| Flaherty & Crumrine Preferred and Income Opportunity Fund | |||